Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Slides:

Advertisements

Similar presentations

Introduction to Autoimmunity Alon Monsonego, Ph.D. The department of Microbiology and Immunology Tel:

Advertisements

Lecture #10 Aims Describe T cell maturation and be able to differentiate naïve and effector T cells. Differentiate the development and functions of Th1.

Activation of T Lymphocytes

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Tumor Immunity: Exploring the Role of a Checkpoint

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Cell-mediated disease mechanisms of lupus nephritis

Jacques F.A.P. Miller, Michel Sadelain Cancer Cell

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Neutrophils in liver inflammation

Figure 5 Dendritic cells in liver inflammation

Figure 2 Immune-escape mechanisms of CTCs in the peripheral blood

Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4 antibodies. Mechanisms mediating the clinical activities of anti-PD-1/PD-L1/CTLA-4.

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Figure 1 Induction of immune tolerance

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 3 Altered adaptive immune functions after sepsis

Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 3 Natural and imatinib-induced immunosurveillance in gastrointestinal tumours (GISTs) Figure 3 | Natural and imatinib-induced immunosurveillance.

Figure 7 Clinical options for HCC therapy

Figure 1 Immune mechanisms in liver homeostasis

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Classification of immunotherapies

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 CAR-T-cell design

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 6 Combination therapy for HCC

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Nat. Rev. Urol. doi: /nrurol

Figure 4 Macrophage-targeting antitumour treatment approaches

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Emerging models of antibody-mediated rejection (ABMR) and

Figure 4 Macrophages in liver inflammation

Leonardo V. Riella, Mohamed H. Sayegh Kidney International Supplements

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Diverse molecular mechanisms of long non-coding RNAs

Figure 1 The role of CTLA4 and PD1 in T cell activation

Figure 2 Approaches to improve CAR-T-cell therapy

during the alloimmune response

Figure 2 Site of action of checkpoint inhibitors and agonists being

Figure 2 Effects of imatinib on components of the anticancer immunosurveillance system Figure 2 | Effects of imatinib on components of the anticancer immunosurveillance.

Mechanisms of immune escape in the tumor microenvironment.

Figure 6 Innate lymphoid cells in liver inflammation

Nat. Rev. Nephrol. doi: /nrneph

Mechanism of CTLA-4-induced immunosuppression.

Nat. Rev. Endocrinol. doi: /nrendo

Johan Botling, MD, PhD, Martin Sandelin, MD, PhD

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Figure 1 Mechanisms of action of immunotherapy modalities

Volume 143, Issue 1, Pages (July 2012)

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Urol. doi: /nrurol

Deciphering and Reversing Tumor Immune Suppression

Figure 3 Underlying mechanisms of TREG cells in atherosclerosis

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Cell-mediated immunity Regulation of the immune response

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Releasing the Brakes on Cancer Immunotherapy

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Presentation transcript:

Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.173 Figure 3 Activation of antitumour responses by the checkpoint-blocking antibody anti-CTLA-4 Figure 3 | Activation of antitumour responses by the checkpoint-blocking antibody anti-CTLA-4. Upper panel: CTLA-4 is transported to the cell membrane of activated T cells and outcompetes CD28 for binding to CD80/86 expressed on the membrane of APCs, depriving T cells of essential co-stimulatory signals. CTLA-4 blockade reconstitutes productive T-cell responses. Lower panel: CTLA-4 is expressed by TREG cells, which sequester CD80/86 on the APC membrane. CD80/86–CTLA-4 ligation induces APCs to secrete IDO and IL-10, which display strong immunosuppressive activities. CTLA-4-blocking antibodies reinvigorate T-cell responses and alleviate the immunosuppressive tumour environment via ADCC-mediated TREG cell elimination. Abbreviations: ADCC, antibody-dependent direct cytotoxicity; APC, antigen-presenting cell; CTLA-4, cytotoxic T-lymphocyte protein 4; IDO, indoleamine 2,3-dioxygenase; NK, natural killer; TCR, T-cell receptor; TREG cell, regulatory T cell. Prieto, J. et al. (2015) Immunological landscape and immunotherapy of hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2015.173